Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

The subcutaneous Perjeta-Herceptin formulation, Phesgo, was a top driver of sales growth in the first quarter of 2025.

Etiome will use its Temporal Biodynamics platform to stage serious, progressive chronic diseases and develop targeted therapeutics.

The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.